Some women will develop this in adulthood. Cardiomyopathy can be associated with atrial fibrillation and embolic strokes. Cardiac conduction abnormalities can occur. Wolff-Parkinson-White syndrome is a common conduction pattern in Danon disease. Symptoms in females progress more slowly than in males. Some females may have visual disturbances, and/or retinal pigment abnormalities
Danon Disease is rare and unfamiliar to most physicians. The milder and more subtle symptoms in females can make it more difficult to diagnose females with Danon Disease

Causes
Although the genetic cause of Danon Disease is known, the mechanism of disease is not well understood. Danon disease involves a genetic defect (mutation) in a gene called LAMP2, which results in a change to the normal protein structure. While the function of the LAMP2 gene is not well understood, it is known that LAMP2 protein is primarily located in small structures within cells called lysosomes. Genetics
It is associated with LAMP2. The status of this condition as a GSD has been disputed. Diagnosis
Making a diagnosis for a genetic or rare disease can often be challenging. Healthcare professionals typically look at a persons medical history, symptoms, physical exam, and laboratory test results in order to make a diagnosis. The following resources provide information relating to diagnosis and testing for this condition. If you have questions about getting a diagnosis, you should contact a healthcare professional. Testing Resources
The Genetic Testing Registry (GTR) provides information about the genetic tests for this condition. The intended audience for the GTR is health care providers and researchers.
Urinary preparations
Purified urinary FSH (75 IU FSH and ≤ 2 IU of LH)Generic
urofollitropin for injection, purified.Brands
Bravelle, U.S., (≤ 2 IU LH)
Metrodin, U.S. and Canada, (≤ 1 IU LH)
Fertinorm Hp, (Canada)Highly purified urinary FSH (75 IU FSH and ≤ 0.1 IU LH/1000 IU FSH)Generic
urofollitropin for injection, (highly) purified.Dosage
typically 75 - 300, but as high as 600 IU / dayBrands
Fertinex (≤ 0.1 IU LH/1000 IU FSH)

Recombinant preparations
Follitropin alfaGeneric
Follitropin alfa injectionBrandsGonal-f
Cinnal-f
Fertilex
Ovaleap
BemfolaFollitropin betaGeneric
follitropin beta injectionBrands
Follistim AQ
PuregonFollitropin deltaGeneric
follitropin delta injectionBrands
RekovelleThe package insert for Gonal-f states that based on physio-chemical tests and bioassays that follitropin beta and follitropin alfa are indistinguishable. Two studies showed no difference. However, a more recent study showed there may be a slight clinical difference, with the alfa form tending towards a higher pregnancy rate and the beta form tending towards a lower pregnancy rate, but with significantly higher estradiol (E2) levels.The package insert for Puregon states that structural analysis shows that the amino acid sequence of follitropin beta is identical to that of natural human follicle stimulating hormone (hFSH). Further, the ogliosaccharide side chains are very similar, but not completely identical to that of natural hFSH. However, these small differences do not affect the bioactivity compared to natural hFSH. Gonal-f was approved for medical use in the European Union in October 1995.Puregon was approved for medical use in the European Union in February 1996.Rekovelle was approved for medical use in the European Union in December 2016. Biosimilars
Ovaleap was approved for medical use in the European Union in September 2013.